Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

SACT followed by radical RT (conventional or SABR) to the primary and SABR to the metastatic sites.

The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases

Radical Radiotherapy (Conventional RT and SABR)

There is no intervention in the control group, patients will receive SACT. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines.

Non-investigational SACT

Ka Man Mak

Crispin Dr Hiley

Ruth Dr Eakin

Qamar Dr Ghafoor

Charles Dr Comins

Alex Dr Martin

Stephen Dr Harrow

Veni Dr Erzhil

Kevin Dr Frank

Thiagarajan Dr Sridhar

Shahreen Dr Ahmad

John Dr Conibear

Merina Dr Ahmed

Corinne Dr Faivre-Finn

Clive Dr Peedell

Phillip Dr Atherton

Karen Dr Foweraker

Matthew Dr Hatton

Andrew Dr Bates

Anthony Pope

Fiona McDonald

The trial will assess the addition of stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy (SACT) in patients with oligometastatic non-small cell lung cancer. Patients will be randomised to receive either standard treatment alone (SACT) or standard treatment with conventional radiotherapy (RT) and SABR.

SARON is a confirmatory phase III study examining the efficacy and safety of stereotactic ablative radiotherapy (SABR) and conventional radiotherapy (RT) alongside standard chemotherapy in patients with oligometastatic non-small cell lung cancer.

Current treatment for this group of patients is systemic anti-cancer therapy. The choice of SACT is determined by the treating clinician and will be supplied from hospital commercial stock, and prepared and administered according to institutional guidelines. There is sufficient evidence regarding the safety of SABR, its effect on local control and a possible impact on overall survival. This trial will further examine overall survival, progression free survival and local control, as well as toxicity, feasibility, patient reported outcomes and health resource use.

There will be a feasibility analysis performed after 50 patients have been randomised. This will assess the practicality of achieving recruitment targets, logistics of delivering the experimental treatment and the potential for contamination (as patients may seek SABR outside of the trial if randomised to the non SABR arm). There will also be a parallel thoracic SABR safety and feasibility study after recruitment and treatment of 20 patients with thoracic metastases.

This is a multicentre randomised phase III study based on patients with oligometastatic NSCLC.

Trial arms:

Control Arm: systemic anti-cancer therapy alone (SACT) Experimental Arm: SACT plus radical RT to primary and SABR and/or SRS to metastases

Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase III Trial

The trial will investigate the impact of the addition of radical conventional and stereotactic radiotherapy to standard systemic therapy on overall survival

The trial will investigate the impact of the addition of radical conventional and stereotactic radiotherapy to standard systemic therapy on progression free survival

Safety analyses will be performed on all patients who received at least one dose of chemotherapy or fraction of SRT post-randomisation. Radiotherapy-related toxicity and early and late toxicity will be investigated. Adverse events will be compared between the two groups, as well as dose delays, reductions and compliance to chemotherapy and radiotherapy.

The trial will investigate the impact of the addition of radical conventional and stereotactic radiotherapy to standard systemic therapy on local tumour control

The health related quality of life for each treatment arm will be assessed.

Spots Global Cancer Trial Database for radical radiotherapy (conventional rt and sabr)